Linking CAR-T's Cytokine Releases Syndrome Risk To Common Biomarkers In New Study

By Annalee Armstrong, Senior Editor

As CAR T-cell therapy becomes more common in oncology, predicting the patients who may experience the life threatening complication called cytokine release syndrome (CRS) is becoming more important. But while many companies are studying these therapies, trials tend to be small, meaning it’s difficult to ascertain which patients might be at risk. 

A clinical trial software provider rolled out a new study at the 2022 American Society of Clinical Oncology (ASCO) conference that pooled data from 542 patients across multiple clinical trials that have been conducted with CAR-T therapies in an effort to gain more insight into which patients are likely to experience CRS.